The company is undertaking studies to look into the safety and efficacy of its molecules SUN-1334H, SUN-597 and SUN-44
The company is undertaking various studies to look into the safety and efficacy of its molecules SUN-1334H, SUN-597 and SUN-44, Sun Pharma Advanced Research Company Chairman and Managing Director Dilip Shanghvi said.
"Our lead molecule SUN-133H is an anti-allergic for use in seasonal allergic rhinitis, perennial allergic rhinitis, chronic idiopathic urticaria and allergic conjunctivitis. It is being developed for oral use as well as topical use, as eye drops and nasal drops," he added.
Shanghvi was addressing the 7th annual general meeting (AGM) of the company.
The company has already completed the phase II study to assess the efficacy of the opthalmic formulation of the molecule in the US in which it was shown to be safe and well tolerated.
Another molecule SUN-597 is also undergoing clinical trials for the treatment of inflammation of airway, skin, eye and gastrointestinal tract, Shanghvi said.
The company is also developing 'SUN-44' a prodrug for the treatment of neuropathy and seizures. The Investigational New Drug (IND) is approved in India and phase-I is planned in the FY'3.
A prodrug is a drug administered in an inactive (or significantly less active) form. It is generally used for absorption, distribution, metabolism, and excretion optimisation.
Sun Pharma Advanced Research Company was demerged from Sun Pharma as a pharma research and drug discovery company in 2007.
Sebi has dismissed matters that alleged delaying implementation of norms related to insider trading by wind turbine maker Suzlon Energy's two ...